Lung Carcinoma

Ba/F3 cells expressing the EML4-ALK S1206Y variant were treated with ceritinib, and survival GI50 value of 1.5 nM was obtained, which compares favorably with GI50 of 1.7 for the highly ceritinib sensi… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

The S1206Y mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.

PMID 22277784 · Katayama et al., 2012 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing EML4-ALK fusion (a known sensitizing alteration to crizotinib) and an ALK S1206Y co-mutation, demonstrated resistance to crizotinib treatment compare… (full text at CIViC)

PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

Ba/F3 cells expressing EML4-ALK with 1151 Tins treated with alectinib had an IC50 of 165.7 nM, 16x higher than those expressing EML4-ALK wildtype variant 1. EML4-ALK variant 1 expressing H3122 NSCLC c… (full text at CIViC)

PMID 22277784 · Katayama et al., 2012 · Open in CIViC

Treatment of Ba/F3 cells expressing EML4-ALK 1151 insT with TAE684 produced an IC50 value (28.3 nM) 20x higher cells expressing EML4-ALK wildtype variant 1. The crizotinib resistant clones were produc… (full text at CIViC)

PMID 22277784 · Katayama et al., 2012 · Open in CIViC

The EML4 ALK variant 1 containing NSCLC cell line H3122 is highly sensitive to alectinib, and an alectinib resistant derivative cell line H3122 CHR-A1 was generated by incubation of H3122 in increasin… (full text at CIViC)

PMID 25228534 · Katayama et al., 2014 · Open in CIViC

The V1180L mutation in the kinase domain of rearranged ALK was found in an alectinib resistant cell line named H3122 CHR-A1, which was derived from the alectinib sensitive EML4-ALK variant 1 containin… (full text at CIViC)

PMID 25228534 · Katayama et al., 2014 · Open in CIViC

A 45-year-old non-smoking female patient was diagnosed with a stage IV lung adenocarcinoma and magnetic resonance imaging showed multiple brain metastases. Targeted NGS analysis on the pleural biopsy … (full text at CIViC)

PMID 36419889 · Lazzari et al., 2022 · Open in CIViC

The paper mentions a 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer initially treated with carboplatin/paclitaxel chemotherapy. Upon identification of an … (full text at CIViC)

PMID 34625502 · Murray et al., 2021 · Open in CIViC

A patient with lung adenocarcinoma showed a double ALK fusion, EML6 exon1-ALK exon20 and FBXO11 exon1-ALK exon20. The patient received Crizotinib 250 mg twice daily and eventually showed partial respo… (full text at CIViC)

PMID 30368418 · Lin et al., 2018 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

Cell proliferation analysis of NIH 3T3 cells harboring the A775_G776insYVMA insertion exhibit an increase of colony formation in soft agar compared with a wild-type ERBB2 and cells with ERBB2 D845A ki… (full text at CIViC)

PMID 22908275 · Greulich et al., 2012 · Open in CIViC

In a Phase II trial, patients with NSCLC haboring exon 20 HER2-activating mutation received afatinib. The interim analysis, evaluating the 12-week status of the first nine patients.Five patients (55.6… (full text at CIViC)

PMID 30825613 · Dziadziuszko et al., 2019 · Open in CIViC

Twenty-eight patients with heavily pretreated stage IV NSCLC had a documented ERBB2 mutation by local testing. Ten patients had pA775_G776insYVMA variants, 2 had M774dup variants, and 16 were unspecif… (full text at CIViC)

PMID 30096481 · Peters et al., 2018 · Open in CIViC

Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. 4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a… (full text at CIViC)

PMID 25899785 · Kris et al., 2015 · Open in CIViC

155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to E… (full text at CIViC)

PMID 23470965 · Yu et al., 2013 · Open in CIViC

In this phase II basket trial, 18 patients with advanced HER2-mutant lung adenocarcinomas were enrolled to receive ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression.… (full text at CIViC)

PMID 29989854 · Li et al., 2018 · Open in CIViC

Ninety patients (pre-treated with a median of 2 lines of therapy) with Non-Small Cell Lung Cancer harbouring HER2 exon 20 insertion mutations were treated with poziotinib. The ORR was 27.8% (95% CI, 1… (full text at CIViC)

PMID 34843401 · Le et al., 2022 · Open in CIViC

Eighty pre-treated patients with Non-Small Cell Lung Cancer harbouring HER2 exon 20 insertions were treated with poziotinib. The ORR Was 39% (95% CI, 28%-50%), and 80% of the patients had a tumour red… (full text at CIViC)

PMID 36958688 · Cornelissen et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

In an in vitro study, Ba/F3 cells expressing ERBB2 G776insV_G/C mutation demonstrated decreased sensitivity to erlotinib treatment (IC50: 0.28 umol/L vs. 0.009 umol/L) compared to Ba/F3 cells expressi… (full text at CIViC)

PMID 16818618 · Shimamura et al., 2006 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

In this phase II study (NCT00818441) of dacomitinib in HER2 amplified or mutant NSCLC tumors, three of 26 patients with HER2 p.P780_Y781insGSP or p.M774delinsWLV showed partial responses of duration b… (full text at CIViC)

PMID 25899785 · Kris et al., 2015 · Open in CIViC

In a phase 2 trial, 152 metastatic NSCLC patients harboring mutations in ERBB2 (HER2) treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 mg/kg) resulted in clinic… (full text at CIViC)

PMID 37694347 · Goto et al., 2023 · Open in CIViC

The authors report a case series where one patient with lung adenocarcinoma harbored ERBB2 variant H878Y (exon 21). Case 2, a 59-year-old male, received Trastuzumab deruxtecan (T-DXd) (5.0 mg/kg once … (full text at CIViC)

PMID 40873587 · Meng et al., 2025 · Open in CIViC

A Phase II study for use of Afatinib in non- or light smokers with lung adenocarcinoma. Three patients with metastatic lung adenocarcinomas bearing mutations in the kinase domain of HER2 gene were ide… (full text at CIViC)

PMID 22325357 · De Grève et al., 2012 · Open in CIViC

This was a retrospective study of patients with advanced HER2-mutant NSCLC who had undergone varied courses of treatment. All tumors were adenocarcinoma with in-frame HER2 exon 20 insertions. In pat… (full text at CIViC)

PMID 26598547 · Mazières et al., 2016 · Open in CIViC